Holen Sie sich die Stockscreener-App
135.42
0.34%
0.46
Handel nachbörslich:
135.42
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
What Analysts Are Saying About Neurocrine Biosciences Stock - Benzinga
Neurocrine Biosciences launches Crenessity in USA - The Pharma Letter
Needham & Company LLC Reaffirms "Hold" Rating for Neurocrine Biosciences (NASDAQ:NBIX) - MarketBeat
Neurocrine launches CRENESSITY for adrenal hyperplasia in US By Investing.com - Investing.com South Africa
Neurocrine Bioscience’s CRENESSITY Becomes Commercially Available In The U.S. - Contract Pharma
Neurocrine launches CRENESSITY for adrenal hyperplasia in US - Investing.com
Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia - PR Newswire
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Ingrid Delaet Sells 1,091 Shares - MarketBeat
Neurocrine Biosciences chief regulatory officer sells $147,285 in shares - Investing.com
Neurocrine Biosciences chief regulatory officer sells $147,285 in shares By Investing.com - Investing.com UK
Neurocrine Biosciences' SWOT analysis: stock outlook mixed amid pipeline setbacks - Investing.com Canada
Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth - Seeking Alpha
Tidal Investments LLC Acquires 5,197 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
HighTower Advisors LLC Lowers Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine wins FDA OK for first-in-class CAH drug - The Pharma Letter
Franklin Resources Inc. Sells 144,114 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
FDA Tracker: Neurocrine, Checkpoint Score FDA Approvals - BioSpace
Neurocrine’s First New CAH Treatment in 70 Years Gets FDA Approval - geneonline
Neurocrine Lands FDA Nod for First New Treatment in Decades for Rare Endocrine Disorder - MedCity News
Neurocrine’s Crenessity Is The First New Drug For CAH In 70 Years - Citeline News & Insights
Blockbuster bound? Neurocrine’s hyperplasia drug approved - BioWorld Online
Neurocrine Jumps After Snagging FDA Approval For A First-In-Decades Drug - Yahoo! Voices
Neurocrine Biosciences (NASDAQ:NBIX) Trading 5% HigherHere's What Happened - MarketBeat
Novo builds up manufacturing; Pepgen Duchenne trial put on hold - BioPharma Dive
Neurocrine Biosciences rises on FDA nod for CAH drug By Investing.com - Investing.com Australia
Neurocrine Biosciences rises on FDA nod for CAH drug - Investing.com
Neurocrine Biosciences (NASDAQ:NBIX) Receives "Outperform" Rating from William Blair - MarketBeat
FDA clears Neurocrine drug for rare adrenal disorder - pharmaphorum
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential - Benzinga
Neurocrine Biosciences (NASDAQ:NBIX) Given Outperform Rating at Wedbush - MarketBeat
Neurocrine Biosciences' (NBIX) Buy Rating Reiterated at HC Wainwright - MarketBeat
Goldman Sachs lifts Neurocrine Bio shares target, buy rating on FDA approval - Investing.com Canada
Launch complexities temper expectations for Neurocrine Bio stock, says BMO Capital - Investing.com Australia
Geode Capital Management LLC Increases Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
(NBIX) Technical Data - Stock Traders Daily
Public Employees Retirement System of Ohio Sells 6,046 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Barclays PLC - MarketBeat
Neurocrine wins FDA approval for CAH therapy - MSN
Neurocrine wins FDA approval for CAH therapy (NBIX:NASDAQ) - Seeking Alpha
Neurocrine Biosciences to Participate at Investor Conferences in December - The Eastern Progress Online
US FDA approves Neurocrine Biosciences’ genetic disorder drug - 1470 & 100.3 WMBD
Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia - Longview News-Journal
US FDA approves Neurocrine Biosciences' genetic disorder drug - Reuters.com
Virtu Financial LLC Invests $1.99 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Tri Ri Asset Management Corp Acquires New Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
4,191 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Purchased by EP Wealth Advisors LLC - MarketBeat
aTyr Pharma Strengthens Board with Neurocrine CCO Eric Benevich, Bolsters Commercial Leadership - StockTitan
Neurocrine Biosciences' SWOT analysis: stock faces mixed pipeline results, regulatory challenges - Investing.com
Tri Ri Asset Management Corp Makes New Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Vestcor Inc Trims Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
XTX Topco Ltd Acquires 5,322 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Wellington Management Group LLP Sells 181,267 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences to Participate at Investor Conferences in September - The Eastern Progress Online
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock Position Cut by Fmr LLC - MarketBeat
Royal London Asset Management Ltd. Purchases 6,060 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Y Intercept Hong Kong Ltd Makes New $3.66 Million Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Shareholders Should Be Pleased With Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price - Simply Wall St
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by State Street Corp - MarketBeat
Verition Fund Management LLC Acquires Shares of 8,325 Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Worldquant Millennium Advisors LLC - MarketBeat
Supporting a Loved One Living with a Mental Health Condition and Tardive Dyskinesia - Main Street Media of Tennessee
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results - The Eastern Progress Online
1.65%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):